Neurology News

As the world continues to grapple with effects of the COVID-19 pandemic, individuals around the globe are still dealing with symptoms of SARS-CoV-2 infection for months, even years, after their initial infection.

Athira Pharma Inc. will proceed in 2023 with several clinical trials for treatments for Alzheimer’s disease, Parkinson’s disease and ALS, the biopharmaceutical company announced in a press release.

A novel 3D video imaging tool has shown high potential for the use of real-time classification of epileptic seizures in hospitals, researchers reported in Scientific Reports.

Migraine has a bidirectional relationship with mental disorders such as anxiety and depression, and one may increase the risk of the other, researchers reported in Cureus.

In patients with active secondary progressive MS, hematopoietic stem cell transplants may delay disability longer than some MS medications, researchers reported in Neurology.

Vistagen announced it has agreed to acquire Pherin Pharmaceuticals Inc., to bolster its efforts on discovery and development of therapeutics to treat a range of psychiatric and neuropsychiatric conditions.

A congressional investigation found the FDA’s interactions with Biogen were “atypical and failed to follow” protocol and that the two “inappropriately collaborated” on documentation before the approval of Aduhelm for Alzheimer’s disease.

The blood-based measure of neurofilament light chain was associated with the presence of neuronal injury in those with peripheral neuropathy, according to a systematic review and meta-analysis in JAMA Network Open.

People with MS who are being treated with rituximab are strongly encouraged to receive mRNA SARS-CoV-2 vaccines and booster doses more than 6 months after their last rituximab infusion, researchers reported in JAMA Network Open.

Singing may be a potential tool to promote communicative and psychosocial outcomes among patients with post-stroke aphasia, researchers reported in Brain Communications.